Liraglutide

Overview

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a once-daily injectable peptide medication that has been approved for the treatment of type 2 diabetes and, separately, for chronic weight management. It is marketed under the brand name Victoza for diabetes and Saxenda for weight management, with the two products differing in their approved indications and dosing. Liraglutide represents an important milestone in the GLP-1 drug class and is a predecessor to the later, longer-acting agent semaglutide.

As an approved medicine, liraglutide has been studied in large, well-conducted clinical trial programs, including the LEADER trial in people with type 2 diabetes and cardiovascular risk, and the SCALE program in weight management. These studies provide a substantial evidence base that distinguishes liraglutide sharply from the many investigational or research-grade peptides that lack rigorous human data.

Because it is a peptide that must be injected and requires daily administration, liraglutide differs from once-weekly successors, a practical distinction that has shaped prescribing as newer agents have emerged. Nonetheless, it remains a clinically established and widely used therapy.

How it works

Liraglutide mimics the natural incretin hormone GLP-1, which the gut releases in response to food. By activating GLP-1 receptors, the drug enhances the release of insulin from the pancreas in a glucose-dependent manner, meaning it stimulates insulin mainly when blood sugar is elevated. This glucose dependence helps lower blood sugar while reducing the risk of causing excessively low glucose compared with some other diabetes treatments.

The medication also suppresses glucagon, a hormone that raises blood sugar, and slows the rate at which the stomach empties. Slower gastric emptying contributes to a feeling of fullness and helps moderate the rise in blood sugar after meals. In addition, liraglutide acts on appetite-regulating centers in the brain, reducing hunger and food intake, which underlies its usefulness for weight management.

Structurally, liraglutide is modified to resist rapid breakdown and to bind to the blood protein albumin, extending its duration of action enough to support once-daily dosing. This contrasts with native GLP-1, which is degraded within minutes. The combination of improved glucose control and reduced appetite explains why a single molecule benefits both diabetes and weight-related outcomes.

Clinical evidence

Liraglutide is supported by an extensive clinical trial program. In type 2 diabetes, the LEADER trial evaluated cardiovascular outcomes in people at high cardiovascular risk and is one of the landmark studies in the GLP-1 class, contributing to liraglutide's recognition for cardiovascular considerations alongside glucose lowering. Earlier development trials established its efficacy in reducing blood sugar, often measured by hemoglobin A1c, and in supporting modest weight loss.

For weight management, the SCALE program studied liraglutide at higher doses in people with overweight or obesity, including those with related conditions. These trials supported the approval of Saxenda by demonstrating clinically meaningful weight reduction relative to placebo when combined with diet and lifestyle changes. The evidence positioned liraglutide as one of the first GLP-1 agents specifically approved for obesity.

While liraglutide's results were substantial, subsequent agents in the class, particularly once-weekly semaglutide, demonstrated greater weight reduction in their own trials, which has influenced clinical preferences. Even so, liraglutide's robust, peer-reviewed trial data and regulatory approvals make it a well-validated therapy, and it remains a reference point for understanding how GLP-1 receptor agonists perform in real clinical populations.

Dosing & side effects

Liraglutide is a prescription medication administered by once-daily subcutaneous injection, and its use should be directed by a qualified healthcare provider. The approved diabetes product (Victoza) and weight management product (Saxenda) use different dose ranges, and treatment is typically started low and increased gradually to improve tolerability. This guide does not provide specific dosing regimens; the appropriate dose and titration must be individualized by a clinician based on the indication and the patient.

The most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, which are often most pronounced when starting or increasing the dose and tend to lessen over time. Slower gastric emptying contributes to these effects. Because liraglutide can affect appetite and digestion, gradual dose escalation is used to reduce discomfort.

More serious considerations have been described in product labeling for the GLP-1 class, including pancreatitis, gallbladder problems, and, based on rodent studies, a boxed warning regarding thyroid C-cell tumors that leads to contraindications in people with certain thyroid cancer histories. Patients should discuss their full medical history with a prescriber. As an approved drug, liraglutide should be obtained and used only under medical supervision rather than from unregulated sources.

Legal status

Liraglutide is a fully approved prescription medication. The U.S. Food and Drug Administration approved it for type 2 diabetes under the brand name Victoza and later for chronic weight management under the brand name Saxenda, and it has corresponding approvals from the European Medicines Agency and other regulators. It is a legitimate, regulated pharmaceutical available only by prescription and dispensed through licensed pharmacies.

Because it is an established medicine rather than a research chemical, liraglutide is manufactured under pharmaceutical quality standards and accompanied by approved labeling that details its indications, dosing, warnings, and contraindications. This regulatory status is a key distinction from many peptides discussed in encyclopedic resources, which lack approval and are sold only for research use.

Patients should be cautious about products marketed online that claim to contain liraglutide or GLP-1 peptides outside of legitimate pharmacy channels, as these may be counterfeit, improperly formulated, or unsafe. The appropriate path to using liraglutide is through a healthcare provider who can confirm it is suitable, manage dosing and monitoring, and ensure the medication comes from a reputable, regulated source. Its status as an approved therapy reflects a substantial body of evidence and oversight that gray-market products do not share.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). N Engl J Med. 2015. Peer-reviewed study
2. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016. Peer-reviewed study
3. Guo T, Yan W, Cui X, et al. Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis. Mol Med. 2023. Peer-reviewed study
4. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014. Peer-reviewed study
5. Ni XY, Feng XJ, Wang ZH, et al. Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway. Acta Pharmacol Sin. 2024. Peer-reviewed study
6. Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020. Peer-reviewed study